{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gout/supporting-evidence/nsaids/","result":{"pageContext":{"chapter":{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs","depth":2,"htmlHeader":"<!-- begin field b72774da-dcfb-4ce1-9090-cd83a66d0ea5 --><h2>Evidence supporting the use of NSAIDs for an acute attack of gout</h2><!-- end field b72774da-dcfb-4ce1-9090-cd83a66d0ea5 -->","summary":null,"htmlStringContent":"<!-- begin item 482a8763-265e-4ef7-877c-05f015452298 --><!-- end item 482a8763-265e-4ef7-877c-05f015452298 -->","topic":{"id":"7ec7842e-cb8a-5712-bb55-65480a391cb5","topicId":"b578fac4-ab4b-4d7b-9df9-2136b4d90e75","topicName":"Gout","slug":"gout","lastRevised":"Last revised in February 2018","chapters":[{"id":"2e71494e-f9a3-5368-8903-3d2121329748","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738bb44e-1a50-5bc5-8df4-83ac66475493","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69338c48-0d43-5ae0-9591-5ef289880366","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes"},{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update"}]},{"id":"5de6e4cf-e0c8-56e2-a357-3d063b324cd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"86664a1d-e3e5-58c9-957b-56affa17f103","slug":"goals","fullItemName":"Goals"},{"id":"39593d8e-f904-5b99-80e9-e619caf1ec37","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca59f248-a0b2-5f6c-bfcf-2333dc94f1d9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"57ca55f4-826e-5832-85a7-dd89f3486be2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"621c09b7-b5e8-593b-aeb2-fc4a86b884c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b39fbed2-7c0d-5440-a769-bab311a7b4d2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"362edeaf-2f90-506d-b203-f5dbbbfb5835","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a8de4056-6ec0-59ff-911b-561bf7fdb32d","slug":"definition","fullItemName":"Definition"},{"id":"45a8241d-2a2d-5a48-a6d6-2b5ebe02ec27","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"92d229bf-8656-5cfa-aecc-9c069389300f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"79d3b1c2-8d49-55be-99af-41b37c84d582","slug":"complications","fullItemName":"Complications"},{"id":"27dd91cd-92bb-5c2d-8fe8-a184bffce6e7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ddea0193-0c14-53db-8e1e-2e71f514988e","slug":"assessment","fullItemName":"Assessment"},{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations"},{"id":"42a5d4a2-b908-5027-8fb8-f5f336db4c7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5a915955-8e0e-54ae-a1cc-f5875d84d2a2","fullItemName":"Management","slug":"management","subChapters":[{"id":"8a8b4d2a-4efb-5bef-9780-70dc540d41bd","slug":"acute-gout","fullItemName":"Scenario: Acute gout"},{"id":"98793041-11dd-5159-a376-82f5440ee713","slug":"preventing-gout","fullItemName":"Scenario: Preventing gout"}]},{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e7cfef3f-4ab1-5d17-8300-30e91a70eb96","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine"},{"id":"60f4beab-f8fc-50e5-8ed9-5073dd8533ec","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol"},{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat"},{"id":"ff3edf82-1b21-591c-a8a5-a3b40e7386a5","slug":"paracetamol","fullItemName":"Paracetamol"}]},{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"71a86333-9110-5847-a2c2-eabf7903c269","slug":"application-of-an-ice-pack","fullItemName":"Application of an ice pack"},{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2921e0f0-467f-5231-87d0-9fed766653ee","slug":"oral-colchicine","fullItemName":"Oral colchicine"},{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"409d2bc0-16d2-5104-8857-eeb5db2a1ecc","slug":"dietary-measures","fullItemName":"Dietary measures"},{"id":"08526f72-ca5a-50db-94b6-3380365360fd","slug":"colchicine-to-prevent-recurrent-gout","fullItemName":"Colchicine to prevent recurrent gout"},{"id":"a53517a7-6d7e-5d2f-886d-e2a3f1bc27b1","slug":"urate-lowering-drugs-in-prevention","fullItemName":"Urate-lowering drugs in prevention"}]},{"id":"f83d98a9-6ce1-50d4-92ad-dd354662a444","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"568c43a6-b0d8-546e-84d2-45781ce305cc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5b7cac11-c21d-59fc-83d9-bf16d0d3ab0b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0e4d0013-b7bc-5179-ac55-8104dec2762c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d75afbe0-7c3d-504e-b369-e56eac297bad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"45249d1d-8c92-5402-b4f3-108a8a39d94f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"44f1a411-2cf4-55e8-b5e8-266cd568655e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","slug":"supporting-evidence","fullItemName":"Supporting evidence"},"subChapters":[{"id":"c21ac309-4bab-5ef3-bf2f-bec0563c1ee8","slug":"effectiveness-of-nsaids","fullItemName":"Effectiveness of NSAIDs","depth":3,"htmlHeader":"<!-- begin field a4bdc20b-877b-461f-b13b-640e2a8f3fcb --><h3>Effectiveness of NSAIDs</h3><!-- end field a4bdc20b-877b-461f-b13b-640e2a8f3fcb -->","summary":null,"htmlStringContent":"<!-- begin item eb78773b-7885-416a-b1f4-c1902dd89e6b --><!-- begin field 13f90544-3e71-497b-a8d2-b3fafe5e7b38 --><ul><li>CKS found 12 clinical trials that compared two different NSAIDs 'head-to-head'.<ul><li>No study reported any clinical advantage of one NSAID over another in terms of effectiveness.</li><li>Evidence on adverse effects was inconsistent, although the largest study reported that indometacin (a traditional non-selective NSAID) was associated with more drug-related adverse events than etoricoxib (a cyclooxygenase-2 selective NSAID).</li></ul></li><li>One placebo-controlled trial of 30 people with acute gout compared the nonsteroidal anti-inflammatory drug (NSAID) tenoxicam with placebo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Garcia de la Torre, 1987</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Underwood, 2006b</a>].<ul><li>After 1 day, tenoxicam significantly increased the proportion of people who reported at least a 50% reduction in pain, compared with placebo.</li><li>After 4 days, the response to tenoxicam was rated by the treating physician as 'good or excellent' more often than with placebo.</li></ul></li><li>There are no randomized controlled trials (RCTs) comparing an NSAID with colchicine for the treatment of gout [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Underwood, 2006b</a>].</li><li>A review of RCTs comparing NSAIDs in acute gout reported that, in most reviewed studies, recovery was faster in people treated with an NSAID than in a historical series of untreated people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>].</li></ul><!-- end field 13f90544-3e71-497b-a8d2-b3fafe5e7b38 --><!-- end item eb78773b-7885-416a-b1f4-c1902dd89e6b -->","subChapters":[]},{"id":"f3353b33-79d3-532a-9a27-bb82779d3971","slug":"effect-of-aspirin-on-plasma-urate","fullItemName":"Effect of aspirin on plasma urate","depth":3,"htmlHeader":"<!-- begin field df0ea42e-9a96-4622-8dab-cf240e658f0c --><h3>Effect of aspirin on plasma urate</h3><!-- end field df0ea42e-9a96-4622-8dab-cf240e658f0c -->","summary":null,"htmlStringContent":"<!-- begin item 6384cf6a-dfdd-4e08-a744-d84a0f467a42 --><!-- begin field 71193fe5-9303-4917-8f16-931d755edd47 --><ul><li>There is some concern about the use of aspirin in people with hyperuricaemia and/or gout [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>].</li><li>Much literature on gout refers to aspirin use being a risk factor. However, a review found that results from three observational studies were inconsistent, and concluded that there are no major concerns with the use of aspirin in people with gout [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Schlesinger and Schumacher, 2004</a>]. Case series have found that:<ul><li>Aspirin at more than 3 g/day is uricosuric [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Yu and Gutman, 1959</a>].</li><li>Aspirin 1–2 g/day causes uric acid retention [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Yu and Gutman, 1959</a>].</li><li>Aspirin 75–325 mg/day has variable effects on uric acid excretion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Caspi et al, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Harris et al, 2000</a>].</li></ul></li></ul><!-- end field 71193fe5-9303-4917-8f16-931d755edd47 --><!-- end item 6384cf6a-dfdd-4e08-a744-d84a0f467a42 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}